We previously reported the development and clinical e‹cacy of a 2％ aspirin oral ointment and 2％ ethenzamide oral ointment as hospital preparations for painful lesions of the oral mucosa. This study investigated methods of preparing a more stable oral ointment with a more eŠective analgesic action, using di‰unisal, another salicylic acid derivative, with an analgesic eŠect stronger than that of aspirin. A two-percent di‰unisal oral ointment was prepared similarly to the aspirin ointment using plastibase and CMC Na as the ointment base. From the results of spreadability measurement, a CMC Na content of 20％ was considered appropriate. The stability of di‰unisal in 2％ di‰unisal oral ointment stored at 5°C, 20°C and 30°C, was determined using HPLC, and a high stability of di‰unisal at room temperature for more than 100 days was conˆrmed. We also investigated its antinociceptive eŠect using the Randall-Selitto paw pressure test in rats, which showed that 2％ di‰unisal oral ointment was as eŠective as 2％ aspirin oral ointment. On clinical application of 2 ％ di‰unisal oral ointment to 8 patients with painful oral mucous diseases, it was found to be signiˆcantly ( p＝0.014) more eŠective than 2％ aspirin oral ointment. The results of this study demonstrated that 2％ di‰unisal oral ointment is a clinically useful analgesic for painful oral lesions.
INTRODUCTION
In diseases of the oral mucosa such as ulcerative stomatitis and recurrent aphthous stomatitis, healing may require several weeks or months. Many patients experience pain that makes it di‹cult to eat, sleep or even talk, and a good pain-relieving treatment with prolonged eŠect is required. 1, 2) Several ointments or patch preparations containing steroids (Kenalogoral ointment, Dexaltinoral ointment, Aphthatchand Aphthaseal ) are used for external application to the oral cavity. However, there have been no reports of these ointments being markedly eŠective in relieving pain. Furthermore, the analgesic eŠects of surface anesthesic drugs such as Xylocaine Jellyand Xylocaine Viscoseshow limited duration.
We previously reported the development of 2％ aspirin oral ointment for painful oral lesions and demonstrated the clinical e‹cacy in a placebo-controlled study. 3, 4) Two percent aspirin oral ointment showed a rapid eŠect with essentially no side eŠects. Although aspirin oral ointment has been used for many patients in our hospital, the stability of aspirin in an ointment form has not been su‹cient for patients to use at home and storage in a refrigerator is required. Later, we developed 2％ ethenzamide oral ointment, which was stable at room temperature but the clinical eŠect was not greater than that of 2％ aspirin oral ointment. 5) Therefore, the present study developed a stable oral ointment with a more eŠective analgesic action. For this purpose, we used di‰unisal, another salicylic acid derivative. Di‰unisal is reported to have an analgesic eŠect 3 8 times greater and an anti-in‰ammatory eŠect 1.5 times greater than aspirin. 6, 7) Furthermore, its analgesic eŠect has been reported to be of long duration. 8, 9) We prepared di‰unisal oral ointment and evaluated its stability, analgesic eŠect in a rat model, and clinical e‹cacy in patients with painful oral mucous diseases.
MATERIALS AND METHODS

Reagents
The reagents used were as follows: di‰unisal (Sigma Co., St. Louis, MO, USA); plastibase (Taisho Co., Tokyo, Japan) as an ointment base; carmellos sodium (CMC Na) (Wako Pure Chemicals Co., Osaka, Japan) as an adhesive; liquid para‹n (Maruishi Co., Osaka, Japan) as a solvent and acetonitrile for high-performance liquid chromatography (HPLC) (Wako Pure Chemicals Co.). Kenalogoral ointment (Bristol-Myers Squibb Co., Tokyo Japan) and Dexaltin oral ointment (Nippon Kayaku Co., Tokyo Japan) were purchased from the local distributor. All other reagents were commercially available or analytical-grade products.
Preparation of Oral Ointments
Preliminary clinical application was performed by an oral surgeon to establish the optimal concentration of di‰unisal. When di‰unisal 0.5％, 1％, 2％ and 5％ were tested, the duration of the analgesic eŠect of 2％ di‰unisal oral ointment was the same as that of 5％, and the eŠect was more prolonged than that of 0.5％ and 1％. Thus, 2％ di‰unisal oral ointment was used in this study.
Two percent di‰unisal oral ointments containing 20％ or 40％ CMC Na were prepared as follows. Two g of di‰unisal crystals were ground in a mortar, then 2 g of liquid para‹n was added and mixed well to make a di‰unisal suspension. Then about 20 g of plastibase was gradually mixed in. Twenty g or 40 g of CMC Na was gradually added, then more plastibase was added to make 100 g of ointment. We also prepared 0.5％ di‰unisal ointment containing 20％ CMC Na in the same way. Two percent aspirin oral ointment was prepared according to the previously reported method. 3) Brie‰y, aspirin crystals (2 g) were ground to aˆne powder in a mortar, with a few drops of ethanol added then allowed to evaporate. Plastibase (78 g) was added and mixed well. CMC Na (20 g) was then gradually added, and the mixture was ground to a uniform consistency.
Evaluation of the Spreadability of 2 Di‰u-nisal Oral Ointments
Spreadability is one of the important indices of the ease of the use of ointments. We measured the spreadability of 2％ di‰unisal oral ointment containing 20 or 40％ CMC Na in the base and evaluated the optimal base for di‰unisal ointment.
Spreadability of the 2％ di‰unisal oral ointment was measured using the diameter of the spread from 10 sec to 1000 sec with a spreadmeter (JIS; made by Rigo Co. Tokyo Japan). 10) The measurement was performed at 25±2°C, and spreadability was determined as the mean value of 3 trials. Two percent di‰unisal oral ointments were prepared and stored at 5°C, 20°C and 30°C for 0, 1, 7, 14, 21 and 28 days. For comparison, spreadability was also calculated for Kenalogoral ointment and Dexaltinoral ointment.
Stability of Di‰unisal in 2 Di‰unisal Oral Ointments
The residual di‰unisal concentration in 2％ di‰unisal ointments containing 20％ CMC Na, stored at 5°C, 20°C and 30°C, were measured using HPLC at 1 day, 7 days, 14 days, 28 days, 56 days and 100 days after preparation. The HPLC apparatus consisted of the following components: a NSI 33R pump (Shimadzu Ltd., Kyoto, Japan), a KHP UI 130A sample injector (Kyowa Seimitsu, Tokyo, Japan), a TSK ODS 80TM reverse-phase column (4.6 mm (150 mm I.D., Toso Co., Tokyo, Japan), a SPD 6A ultraviolet absorption detector (Shimadzu Co., Kyoto, Japan), and a HITACHI 561 recorder (Hitachi Ltd., Tokyo, Japan).
For testing, 50 mg of the preserved ointments were added to 10 ml of ethanol containing ‰ufenamic acid (50 mm) as an internal standard. After vigorous mixing, the sample was sonicated for 20 min, 500 ml of the resultant suspension was then added to 500 ml of water, mixed well andˆltered with a Dismic TM 3 JP cartridge (0.5 mm, Advantec Toyo Co., Tokyo, Japan). Twenty ml of theˆltrate was analyzed by HPLC. The mobile phase was 0.1％ tri‰uoroacetic acid in a mixture of acetonitrile-water, 45 : 55, by volume. The ‰ow rate of the mobile phase was 1.0 ml /min and the HPLC column was operated at room temperature. The eluate was monitored at 251 nm. Di‰unisal contents in the ointments were calculated from their peak height ratios to the internal standard using a calibration curve. The mean of 4 estimates was used for calculation. The remaining di‰unisal concentration in the ointment immediately after preparation was normalized as 100％.
Measurement of Di‰unisal Absorption by the Oral Mucous Membrane
Measurement of di‰u-nisal absorption by the oral mucous membrane was carried out using a test patch made of adhesive plastiĉ lm with a 10 mm cotton disk inside (Patch tester TORII, Torii Co., Tokyo, Japan). Six healthy hospital pharmacists participated as subjects. Fifty mg of 2％ di‰unisal oral ointment containing 20％ CMC Na was applied to the cotton part of the test patch. The test patches were a‹xed to the mucous membrane inside of the subject's cheek, and then detached immediately or at 10, 30 and 60 min. The ointment that remained attached to the mucous membrane was collected using a scraper, and combined with the recovered test patch. Then, the quantity of di‰unisal in the test patch was measured using HPLC. When the patch was detached immediately after a‹x-ation to the mucous membrane, the remaining di‰unisal content in the ointment was normalized as 100％. No leakage of ointment from the patch into the space other than the mucous membrane was conrmed by the method reported previously. In brief, 1 ％ gentian violet solution was added as a coloring agent at a ratio of 3 drops to 10 g of ointment, and the ointment was mounted on the test patch and applied to the mucous membrane. No leakage of dye from the test patch to the surrounding mucous membrane was observed.
Antinociceptive Test in Experimental Hyperalgesia
Male Wistar rats (n＝6, supplied by NRC Haruna, Gunma, Japan) weighing 200 230 g were used. The nociceptive threshold against pressure stimuli on the hind paw was determined using the Randall-Selitto method (Analgesy-Meter, Ugo Basile Co., Milan, Italy). 11) Rats showing a basal nociceptive threshold between 75 g and 95 g were selected and 0.1 ml of 20％ brewer's yeast (Tanabe Co., Osaka, Japan) suspension in saline was injected under the plantar skin of the left hind paw. Animals did not show any weight loss or apparent change in grooming behavior during the experimental period. After 5 days, 1 g of 2％ or 0.5％ di‰unisal oral ointment, 2％ aspirin oral ointment or control basal ointment was applied to the hind paw and wrapped with cotton and a latex sac. Basal oral ointment (containing 20％ CMC Na) was used as a control. Application of ointment was renewed after every measurement of nociceptive threshold until 3 h. Nociceptive thresholds were measured just before the application (0 h) of ointment and at 1 h, 2 h, 3 h, 4 h and 5 h after the application. At each time point, the average of three estimations was taken as a threshold value. All threshold values of each rat were normalized to 1 by the value of that rat at 0 h. Threshold measurements were performed in a blind manner in which the measurer was not aware of the ointment applied. Animal experiments were performed according to the guidelines stated in The Guide for Animal Experimentation, Faculty of Medicine, University of Tokyo.
7. Clinical Assessment of Analgesic EŠect Eight patients (3 male and 5 female) between 42 and 61 years of ages who visited the Department of Oral Surgery, Branch Hospital of University of Tokyo, and who experienced pain in the oral mucous membrane were included in this study. All patients gave informed written consent.
First, the oral surgeon made the diagnosis and evaluated the severity of pain according to a 5 grade scale of severe pain, moderate pain, slight pain, tenderness, and no pain. Two percent di‰unisal oral ointment containing 20％ CMC Na was applied to the oral cavity in an amount of 0.1 0.3 g per treatment according to the symptoms. The oral surgeon then interviewed the 8 subjects to assess the analgesic eŠect. Total assessments of ointments were also carried out according to the Standard of Assessment of Analgesic E‹cacy proposed by Saito et al. (Table 1) , in which scores for the degree of pain relief, time of onset and duration were pooled to evaluate the total e‹cacy of the ointment. 12) RESULTS AND DISCUSSION Figure 1 shows the spreadability of each oral ointment after storage at 20°C for 7 days. The Y intercept (at log X＝0) is a parameter of viscosity, and lower values indicate higher viscosity. The Y intercept was 2.524 cm for 2％ di‰unisal oral ointment containing 20％ CMC Na and 2.357 cm for 2％ di‰unisal oral ointment containing 40％ CMC Na. For comparison, we also measured these parameters in commercially available oral steroid ointments, Kenalogand Dexaltin . The Y intercepts were 2.385 cm for Kenalogoral ointment and 2.591 cm for Dexaltinoral ointment. These values were in the range reported to be clinically appropriate for skin ointments (about 2.0 3.5 cm), conˆrming the appropriate viscosity of each ointment. 13 15) The slope a parameter of ointment spreadability, was 0.114 for 2％ di‰unisal oral ointment containing 20％ CMC Na, 0.126 for Kenalogoral ointment, and 0.127 for Dexaltinoral ointment, showing good spreadability, but 0.048 for 2％ di‰unisal oral ointment containing 40％ CMC Na, indicating poor spreadability.
Evaluation of the Spreadability of 2 Di‰u-nisal Oral Ointments
None of the ointment showed changes in spreadability under each storage condition (at 5°C, 20°C or 30°C) for 28 days from immediately after preparation (data not shown). Therefore, in the experiments below, 2％ di‰unisal oral ointment containing 20％ CMC Na was used.
Stability of Di‰unisal in 2 Di‰unisal Oral Ointments
Chart 1 shows the chromatogram of Figure 2 shows changes in the percentage of the residual amount of di‰unisal to the amount immediately after ointment preparation under each condition until 100 days. In 2％ aspirin oral ointment reported previously, the concentration of aspirin as an active ingredient decreased signiˆcantly after storage at 30°C for 50 days. 3) In 2％ di‰unisal oral ointment, there were no changes observed over time even at 30°C up to 100 days, conˆrming adequate stability of ointment at room temperature.
Measurement of Absorption of Di‰unisal from Oral Mucous Membrane
Test patches to which 2 ％ di‰unisal oral ointment was applied were attached to the oral mucous membrane and immediately detached. The mean recovery of di‰unisal among 6 subjects calculated from the residual amount in the patches was 91.0±0.06％ (S.D.). The recovery rate in each subject was used for correction and the residual amounts of di‰unisal in the ointment after designated periods were expressed as the percentage of values immediately after application. In the patch tests of ointment containing gentian violet, the absence of any leakage of ointment from the patches was conˆrmed.
From the residual rate of di‰unisal shown in Fig.  3 , 3％ and 17％ of di‰unisal on the test patch was suggested to have been absorbed through the oral mucosa 10 and 60 minutes after application, respectively. Di‰unisal that reached the lesion through the oral mucosa was considered to produce an analgesic eŠect.
Antinociceptive Test in Experimental Hyperalgesia
As shown in Fig. 4 , the nociceptive threshold force in rats did not increase in the control group to which only basal oral ointment was applied, but was increased in the 2％ aspirin oral ointment group and 2％ di‰unisal oral ointment group. The thresholds after 1 h returned almost to those before the cutaneous injection of 20％ brewer's yeast, indicating adequate alleviation of pain. In the 0.5％ di‰unisal oral ointment group, the increase in nociceptive threshold was inadequate. This experiment suggested that the appropriate concentration of di‰unisal in oral ointment is 2％. Table 2 shows the results of pain relief assessment (A). Of the 3 patients who complained of severe pain before treatment, 2 reported no pain (grade 4), and 1 reported tenderness (grade 3), after treatment. The patient who had complained of moderate pain reported no pain (grade 3), and the 4 patients who had complained of slight pain all reported no pain (grade 2) after treatment. The interval until onset of the analgesic eŠect (B) was within 10 minutes (grade 3) in 4 patients and within 20 minutes (grade 2) in 4 patients. The duration of the analgesic eŠect (C) was 5 hours or longer (grade 3) in 6 and 3 hours or longer (grade 2) in 2. Global analgesic e‹cacy (A＋B＋C) was evaluated as remarkable (grade 8 10) in 5 and moderate (grade 5 7) in 3. These results were signiˆcantly better ( p＝0.014) than the previously reported clinical eŠects of 2％ aspirin oral ointment 4) (Mann-Whitney test).
Clinical Assessment of Analgesic EŠect
The pain-relieving eŠect of di‰unisal in the ointment might be ascribed to the inhibitory activity on cyclo-oxygenase in the oral mucous membranes or to the direct analgesic action of di‰unisal at the peripheral sensory nerve endings, as discussed previously for the application of aspirin ointment for postherpetic neuralgia and rheumatalgia. 16, 17) .
From these results, the 2％ di‰unisal oral ointment prepared in this study was suggested to be stable at room temperature for 100 days or longer and to have signiˆcantly greater clinical e‹cacy than 2％ aspirin oral ointment.
In patients with pain associated with lesions of the oral mucosa, it is important not only to identify its cause but also to reduce pain as soon as possible in terms of the patient's quality of life. There are only a few commercially available oral analgesic ointments, all of which contain steroids. Therefore, the development of di‰unisal oral ointment may increase treatment options for patients with painful oral lesions.
We will carry out further pharmaceutical evaluations of this ointment, including consistency, adhesiveness, disintegration, and bleeding 18) as well as evaluation of the base to develop a more useful di‰unisal ointment. Moreover, we also intend to evaluate non-steroidal anti-in‰ammatory analgesic agents other than salicylic acid.
